2,6-difluoro-3,4-dihydroxyphenylalanine has been researched along with Benign Neoplasms, Brain in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pretze, M; Wängler, B; Wängler, C | 1 |
| Chen, W; Cloughesy, T; Czernin, J; Fueger, BJ; Geist, CL; Lai, A; Nghiemphu, P; Phelps, ME; Schiepers, C; Silverman, DH; Walter, MA | 1 |
1 review(s) available for 2,6-difluoro-3,4-dihydroxyphenylalanine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Humans; Mental Disorders; Movement Disorders; Radioactive Tracers; Radionuclide Imaging | 2014 |
1 other study(ies) available for 2,6-difluoro-3,4-dihydroxyphenylalanine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Topics: Adult; Aged; Brain Neoplasms; Dihydroxyphenylalanine; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Young Adult | 2010 |